A	O
novel	O
HER2	S-GENE
gene	O
body	O
enhancer	O
contributes	O
to	O
HER2	S-GENE
expression	O
.	O


The	O
transcriptional	O
regulation	O
of	O
the	O
human	O
epidermal	B-GENE
growth	I-GENE
factor	I-GENE
receptor	I-GENE
-	I-GENE
2	E-GENE
(	O
HER2	S-GENE
)	O
contributes	O
to	O
an	O
enhanced	O
HER2	S-GENE
expression	O
in	O
HER2	S-GENE
-	O
positive	O
breast	O
cancers	O
with	O
HER2	O
gene	O
amplification	O
and	O
HER2	O
-	O
low	O
or	O
HER2	O
-	O
negative	O
breast	O
cancers	O
following	O
radiotherapy	O
or	O
endocrine	O
therapy	O
,	O
and	O
this	O
drives	O
tumorigenesis	O
and	O
the	O
resistance	O
to	O
therapy	O
.	O


Epigenetic	O
mechanisms	O
are	O
critical	O
for	O
transcription	O
regulation	O
,	O
however	O
,	O
such	O
mechanisms	O
in	O
the	O
transcription	O
regulation	O
of	O
HER2	S-GENE
are	O
limited	O
to	O
the	O
involvement	O
of	O
tri	O
-	O
methylated	O
histone	O
3	O
lysine	O
4	O
(	O
H3K4me3	O
)	O
and	O
acetylated	O
histone	O
3	O
lysine	O
9	O
(	O
H3K9ac	O
)	O
at	O
the	O
HER2	S-GENE
promoter	O
region	O
.	O


Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
enhancer	O
in	O
the	O
HER2	S-GENE
3	O
'	O
gene	O
body	O
,	O
which	O
we	O
have	O
termed	O
HER2	S-GENE
gene	O
body	O
enhancer	O
(	O
HGE	O
)	O
.	O


The	O
HGE	O
starts	O
from	O
the	O
3	O
'	O
end	O
of	O
intron	O
19	O
and	O
extends	O
into	O
intron	O
22	O
,	O
possesses	O
enhancer	O
histone	O
modification	O
marks	O
in	O
specific	O
cells	O
and	O
enhances	O
the	O
transcriptional	O
activity	O
of	O
the	O
HER2	B-GENE
promoters	E-GENE
.	O


We	O
also	O
found	O
that	O
TFAP2C	S-GENE
,	O
a	O
known	O
regulator	O
of	O
HER2	S-GENE
,	O
binds	O
to	O
HGE	O
and	O
is	O
required	O
for	O
its	O
enhancer	O
function	O
and	O
that	O
DNA	O
methylation	O
in	O
the	O
HGE	O
region	O
inhibits	O
the	O
histone	O
modifications	O
characterizing	O
enhancer	O
and	O
is	O
inversely	O
correlated	O
with	O
HER2	S-GENE
expression	O
in	O
breast	O
cancer	O
samples	O
.	O


The	O
identification	O
of	O
this	O
novel	O
enhancer	O
sheds	O
a	O
light	O
on	O
the	O
roles	O
of	O
epigenetic	O
mechanisms	O
in	O
HER2	S-GENE
transcription	O
,	O
in	O
both	O
HER2	O
-	O
positive	O
breast	O
cancer	O
samples	O
and	O
individuals	O
with	O
HER2	O
-	O
low	O
or	O
HER2	O
-	O
negative	O
breast	O
cancers	O
undergoing	O
radiotherapy	O
or	O
endocrine	O
therapy	O
.	O
